2C-P Stats - Substance Search

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

5-HT2B receptor agonist (partial)

5-HT2C receptor agonist (partial)

5-HT1A receptor agonist

TAAR1 agonist (rodents)

Other

Dopamine transporter phosphorylation

Subjective Effects

Physical

Spontaneous tactile sensations: The body high of 2C-P is intense but, in comparison to 2C-E or 2C-B, it can be considered mild though is still capable of becoming very powerful and highly physically euphoric. It is similar yet distinct from the body high experienced on 2C-E, 2C-B, and LSD. The sensation itself can be described as intense and will manifest itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves. This is coupled by an equally intense yet slightly uncomfortable energetic pins and needles sensation that constantly encompasses a person's entire body and a slight warm glow that manifests itself much less consistently than the other two physical components. All of these are capable of becoming very physically euphoric but can be described as proportionally intense with the visual and cognitive effects when compared to LSD.
Stimulation: In terms of its effects on the physical energy levels of the tripper, 2C-P is usually considered to be very energetic and stimulating in a fashion that is quite comparable to that of MDMA.
Sexual arousal: A commonly felt physical component of the 2C-P trip is the way in which it heightens and enhances sexual arousal. When experienced, this sensation is not overwhelming or out of control but simply remains something that the tripper is constantly aware of. If sexual activities of any kind are engaged in, they are found to be immensely more pleasurable beyond anything that could be possible sober with orgasm becoming difficult to reach but completely possible to obtain. When obtained, the orgasm itself is capable of temporarily increasing the effects of the drug, most commonly experienced as visual effects dramatically increasing in a short yet powerful burst.
Increased bodily control
Tactile enhancement
Nausea: Mild to extreme nausea is consistently reported when consumed in moderate to high dosages and either passes once the tripper has vomited or gradually fades by itself as the peak sets in.
Temperature regulation loss

Cognitive

The head space of 2C-P is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.

Current mind state enhancement
Thought acceleration
Feelings of fascination, importance and awe
Time distortion
Introspection
Personal bias suppression
Conceptual thinking
Ego suppression, loss and death
Thought loops
Feelings of interdependent opposites
Delusions
Unity and interconnectedness

Sensory

Auditory

Enhancements
Distortions
Hallucinations

Visual · Distortions

Visual drifting: (Melting, Flowing, Breathing and Morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion, static in appearance, and unrealistic/cartoon-like in style.
Tracers
After images
Texture repetition
Colour shifting
Scenery slicing

Visual · Enhancements

Increased visual acuity
Enhancement of colours
Enhanced pattern recognition

Visual · Hallucinatory States

2C-P produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics, particularly in comparison to other substances within the phenethylamine family.

External hallucinations
Internal hallucinations: In comparison to other psychedelics such as LSD, 2C-P is extremely high in hallucinations embedded within visual geometry. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of religious, spiritual, mystical or transcendental nature in their overall theme.

Forked from Subjective Effect Documentation by Josie Kins, September 2013. Via dose.wiki (CC0).

Toxicity

PsychonautWiki

The toxicity and long-term health effects of recreational 2C-P use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-P is a research chemical with very little history of human usage. Anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.

Overdose

The LD50 of 2C-P has not been established. However, it is believed that 2C-P is likely to have a smaller therapeutic window compared to other 2C's, meaning a lethal dose may be achieved more easily. In 2017, a 25-year old British female died following the ingestion of a large dose of 2C-P at a music festival.

Addiction & dependence

As a serotonergic psychedelic, 2C-P is considered to have a low potential for abuse and dependence. Tolerance to the effects of 2C-P is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption).

Effect Profile

Curated + 84 Reports

Psychedelic 8.8

Strong visuals, headspace, and auditory effects with strong body load

Visual Intensity×3

10103.7

Headspace Depth×3

105.92.4

Auditory Effects×1

10103.6

Body Load / Somatic Effects×1

10105.6

Catalog Erowid BlueLight

Based on reports from:

Effect Index Horrid Body Load Glowing Thoughts — nervewing PiHKAL PiHKAL #36: 2C-P Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 2C-P

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Oral

1-3 hours

2-4 hours

4-8 hours

3-6 hours

8-48 hours

Total: 10-20 hours

Insufflated

15-45 minutes

30 minutes - 1.5 hours

4-8 hours

3-6 hours

8-24 hours

Total: 10-16 hours

Community Effects

TripSit

Positive

visual enhancement

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Unknown in humans (long clinical duration suggests slow clearance and/or prolonged receptor engagement)

Addiction Potential

Not associated with compulsive use; physical dependence is very unlikely. Psychological habituation possible with frequent use or coping‑motivated use.

Tolerance Decay

Full tolerance 1d Half tolerance 5d Baseline ~14d

Typical psychedelic acute tolerance appears within the same day and decays over ~1–2 weeks; cross‑tolerance with other serotonergic psychedelics is expected. Data are based on community guidelines for psychedelics generally; specific 2C‑P pharmacokinetics are not established.

Cross-Tolerances

LSD

Psilocybin mushrooms

Mescaline

Other 2C‑x phenethylamines

Experience Report Analysis

Erowid BlueLight

85 Reports

45 Single-substance

2002–2016 Date Range

68 With Age Data

30 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 84 experience reports (45 single-substance Erowid + 39 Bluelight)

84 Reports

137 Effects Detected

65 Positive

54 Adverse

18 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Positive Effects 65

Color Enhancement 53.5% 83%

Visual Distortions 48.8% 83%

Music Enhancement 34.5% 86%

Closed-Eye Visuals 32.1% 88%

Euphoria 32.1% 85%

Visual Trails 30.8% 82%

Stimulation 29.8% 79%

Introspection 26.2% 81%

Surface Breathing 25.6% 81%

Sociability Enhancement 25.6% 80%

Contentment 23.1% 80%

Joy 20.5% 83%

Patterning 20.5% 88%

Geometric Imagery 17.9% 87%

Morphing 17.9% 83%

Body High 16.7% 82%

Empathy 15.5% 80%

Open-Eye Visuals 15.5% 89%

Fractal Imagery 15.4% 89%

Entity Imagery 12.8% 81%

Adverse Effects 54

Body Load 51.3% 78%

Anxiety 45.2% 83%

Nausea 34.5% 86%

Insomnia 30.8% 83%

Fear 23.1% 83%

Thought Disorganization 17.9% 81%

Confusion 16.7% 82%

Vomiting 15.4% 87%

Pupil Dilation 14.3% 83%

Stomach Cramps 12.8% 74%

Jaw Clenching 11.9% 82%

Headache 11.9% 76%

Panic 10.3% 85%

Tremor 10.3% 81%

Disrupted Sleep Architecture 10.3% 75%

Appetite Suppression 9.5% 75%

Sweating 8.3% 85%

Motor Impairment 8.3% 75%

Thought Loops 7.7% 80%

Body Temperature Change 7.7% 73%

Show 34 more adverse effects

Depersonalization 7.7% 75%

Taste Distortion 7.7% 82%

Paranoia 7.7% 85%

Tension 7.7% 82%

Focus Suppression 7.7% 73%

Increased Heart Rate 6.7% 70%

Muscle Tension 6.0% 85%

Memory Suppression 6.0% 80%

Hallucination 5.1% 80%

Time Stopping 5.1% 82%

Muscle Twitching 5.1% 80%

Frequent Urination 5.1% 90%

Heaviness 5.1% 82%

Hot Flashes 5.1% 92%

Dizziness 5.1% 85%

Pain Enhancement 5.1% 88%

Sadness 2.6% 80%

Dysphoria 2.6% 75%

Metallic Taste 2.6% 85%

Dry Mouth 2.6% 80%

Chills 2.6% 80%

Temperature Sensitivity 2.6% 80%

Drowsiness 2.6% 80%

Blurred Vision 2.6% 80%

Emotional Blunting 2.6% 70%

Urinary Retention 2.6% 90%

Vasoconstriction 2.6% 80%

Sociability Suppression 2.6% 75%

Lethargy 2.6% 80%

Cold Flashes 2.6% 95%

Temporal Disorientation 2.6% 70%

Muscle Spasm 2.6% 85%

Delusion 2.6% 80%

Ataxia 2.6% 75%

Show 18 neutral or unclassified mentions

Auditory Effects 29.8%

Time Dilation 25.6%

Sedation 20.2%

Hospital 20.0%

Melting/flowing 15.4%

Ego Dissolution 10.7%

Warping 10.3%

Dissociation 8.9%

Restlessness 7.7%

Pitch Shifting 7.7%

Pareidolia 5.1%

Time Distortion 4.8%

Contact-With-Presence 2.6%

Out-Of-Body Experience 2.6%

Distractibility 2.6%

Double Vision 2.6%

Internal Cognitive Split 2.6%

Time Compression 2.6%

Also reported in combinations. In the 40 2C-P reports where another drug was taken too, 8 (20.0%) mention hospital, emergency services or an overdose, 0 (0.0%) a seizure and 0 (0.0%) psychosis. In the 45 single-substance reports: 20.0%, 0.0% and 2.2%. These are not in the figures above: they cannot be put down to 2C-P alone, and a mention is not always something that happened to the writer.

Dose-Response Correlation

How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

Not drawn, too few reports (a dose tier needs 20): Oral Heavy (n=15). Why 20?

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

Median: 10.0 mg IQR: 8.0–10.5 mg n=32

4 reports gave a dose above the typical range (35–75 mg), so they are not in the figures above. 3 of them mention hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

Show the reports

75 mg · mentions hospital, emergency services or an overdose
70 mg · mentions hospital, emergency services or an overdose
50 mg · another drug taken too · mentions hospital, emergency services or an overdose
35 mg · another drug taken too

Real-World Dose Distribution

Erowid

From 77 of 87 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Oral (n=51)

Median: 10.0mg 25th: 8.0mg 75th: 10.5mg 90th: 16.0mg

Insufflated (n=13)

Median: 8.0mg 25th: 5.0mg 75th: 10.0mg 90th: 13.4mg

Rectal (n=7)

Median: 3.0mg 25th: 2.75mg 75th: 6.0mg 90th: 9.6mg

Common Combinations

Most co-occurring substances, as a share of all 85 reports filed under 2C-P; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 58 reports that give one; whiskers are 95% intervals

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Oral

Median: 0.133 mg/kg IQR: 0.11–0.164 mg/kg n=32

4 reports gave a dose above the typical range (0.617–0.852 mg/kg), so they are not in the figures above. 3 of them mention hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

Show the reports

0.852 mg/kg · mentions hospital, emergency services or an overdose
0.824 mg/kg · mentions hospital, emergency services or an overdose
0.649 mg/kg · another drug taken too · mentions hospital, emergency services or an overdose
0.617 mg/kg · another drug taken too

Insufflated

Median: 0.126 mg/kg IQR: 0.085–0.143 mg/kg n=7

Redose Patterns

Redosing behavior across 61 reports

13.1% Redosed

1.2 Avg Doses

240m Median Interval

Legal Status

Controlled internationally under the UN Convention on Psychotropic Substances 1971.

Country	Status	Notes
Austria	2C-P is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).	In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.
Canada	As of October 31, 2016; 2C-P is a controlled substance (Schedule III) in Canada.
China	As of October 2015 2C-P is a controlled substance in China.
Denmark	In Denmark, 2C-P has been added to the list of Schedule B controlled substances.
Finland	Scheduled in "government decree on psychoactive substances banned from the consumer market".
Germany	2C-P is an Anlage I controlled drug.
Japan	2C-P is a controlled substance in Japan effective March 25th, 2015.
Latvia	2C-P is a Schedule I controlled substance.
Sweden	The Riksdag added 2C-P to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of August 16, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2016:80 listed as 2,5-dimetoxi-4-propylfenetylamin.
Switzerland	2C-P is a controlled substance specifically named under Verzeichnis E.
United Kingdom	2C-P is a Class A drug in the UK.
United States	2C-P was placed into Schedule I (with the DEA Drug Code of 7524) making it illegal to possess, distribute and/or manufacture without a license in the United States by an act of the US Congress on July 9, 2012 when US President Barack Obama signed the Synthetic Drug Abuse Prevention Act of 2012 (SDAPA).	The law came into effect on January 4, 2013.

Harm Reduction

drugs.wiki

2C‑P is a highly potent, long‑lasting psychedelic; a small change in dose can cause disproportionately larger effects. The come‑up is often delayed, with some users not reaching clear effects until 3–5 hours; redosing during the come‑up has led to accidental overdosing. Volumetric dosing is strongly advised for accurate sub‑10 mg measurement and to reduce weighing error risk. Compared to 2C‑E, 2C‑P is typically longer in duration and can be more intensely visual with a heavier body load at higher doses. Cardiovascular side‑effects (tachycardia, hypertension, vasoconstriction) and anxiety are reported more often at higher doses or with stimulant combinations; those with cardiovascular disease should avoid. Insufflation has a faster onset but is frequently described as more uncomfortable and physically taxing than oral use. In unregulated markets, powders or pills sold as a '2C' or 'Tusi/pink cocaine' have repeatedly contained no 2C substance and instead mixtures of ketamine/MDMA/stimulants and even traces of fentanyls/benzodiazepines; reagent testing or using a professional drug‑checking service is therefore recommended and avoiding redose is prudent if onset is delayed. U.S. legal status: Schedule I; UK: Class A.

2C-P Stats & Data

Receptor Profile

Receptor Actions

Subjective Effects

Physical

Cognitive

Sensory

Toxicity

Overdose

Addiction & dependence

Effect Profile

Duration Timeline

Community Effects

Tolerance & Pharmacokinetics

Tolerance Decay

Cross-Tolerances

Experience Report Analysis

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 65

Adverse Effects 54

Dose-Response Correlation

Dosage Distribution

Real-World Dose Distribution

Oral (n=51)

Insufflated (n=13)

Rectal (n=7)

Common Combinations

Form / Preparation

Body-Weight Dosing

Oral

Insufflated

Redose Patterns

Legal Status

Harm Reduction

References

Data Sources

Cited References

Additional references